Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,323 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gastrointestinal Anomalies Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cancer Health Assessments Reaching Many

NCT03426878
View directory record Official record
Conditions
Hereditary Cancer Syndrome
Interventions
Modified genetic counseling, Traditional genetic counseling
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 49 Years
Enrollment
967 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
2
States / cities
Denver, Colorado • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 18, 2026, 8:16 AM EDT
Recruiting No phase listed Observational

Natural History of Noncirrhotic Portal Hypertension

NCT02417740
View directory record Official record
Conditions
Cystic Fibrosis, Immunologic Deficiency Syndrome, Turner Syndrome, Congenital Hepatic Fibrosis, Idiopathic Non-Cirrhotic Portal Hypertension
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 18, 2026, 8:16 AM EDT
Completed No phase listed Observational

A Study of Sweat Testing Using a Quantitative Patch

NCT01345617
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Polychrome Medical, Inc.
Industry
Eligibility
2 Days and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Minneapolis, Minnesota • Salt Lake City, Utah • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 18, 2026, 8:16 AM EDT
Completed Phase 1 Interventional Results available

Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin (AAT) Deficiency

NCT00430768
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
rAAV1-CB-hAAT
Biological
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
2
States / cities
Gainesville, Florida • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 18, 2026, 8:16 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis

NCT03911713
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-561, IVA, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
30
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 18, 2026, 8:16 AM EDT
Completed No phase listed Observational

Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.

NCT04038710
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Triple combination therapy
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
12 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 18, 2026, 8:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis

NCT04568980
View directory record Official record
Conditions
Cystic Fibrosis, Contraception
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
562 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 18, 2026, 8:16 AM EDT
Completed Not applicable Interventional

Esophageal Atresia: a Natural Experiment of the Effects of Oral Inoculation on the Gut Microbiome

NCT04901546
View directory record Official record
Conditions
Esophageal Atresia
Interventions
Patient's own saliva
Other
Lead sponsor
Stanford University
Other
Eligibility
Up to 3 Months
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 18, 2026, 8:16 AM EDT
Active, not recruiting No phase listed Observational

CFTR Modulator Effects on Bone and Muscle in Adults With Cystic Fibrosis

NCT04206436
View directory record Official record
Conditions
Cystic Fibrosis, Bone Loss, Muscle Loss
Interventions
Cftr Modulators
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 18, 2026, 8:16 AM EDT
Completed Phase 1 Interventional

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

NCT03329950
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, Pancreatic Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Other Solid Tumors, Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma, Indolent B-cell Lymphomas, Non-Hodgkin Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Waldenstrom's Disease, Marginal Zone Lymphoma, Mucosa Associated Lymphoid Tissue, Small Lymphocytic Leukemia
Interventions
CDX-1140, CDX-301, pembrolizumab, Chemotherapy
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
11
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Oct 18, 2026, 8:16 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

VITamin D and OmegA-3 TriaL: Effects on Mammographic Density and Breast Tissue

NCT02239874
View directory record Official record
Conditions
Benign Breast Disease
Interventions
Vitamin D and fish oil placebo, Fish oil and vitamin D placebo, Vitamin D placebo and fish oil placebo, Vitamin D and fish oil
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
55 Years to 67 Years · Female only
Enrollment
3,894 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 18, 2026, 8:16 AM EDT
Active, not recruiting Not applicable Interventional

Lung Transplant READY CF 2: A Multi-site RCT

NCT06030206
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Investigator-designed lung transplant education resource (Research Intervention), Publicly available transplant education resource (Attention-control)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 18, 2026, 8:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Hepatic Glucose Production and De Novo Lipogenesis in Patients With Cystic Fibrosis

NCT00014781
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 30 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2009 · Synced Oct 18, 2026, 8:16 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria

NCT03520036
View directory record Official record
Conditions
Erythropoietic Protoporphyria (EPP)
Interventions
MT-7117 low dose, MT-7117 high dose, Placebo
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 18, 2026, 8:16 AM EDT
Completed No phase listed Observational

Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract

NCT01770405
View directory record Official record
Conditions
Pancreatic Cyst, Pancreatic Neoplasms, Pancreatic Adenoma, Pancreatic Cancer, Pancreatic Islet Cell Tumors, Lymph Node Mass, Lymphadenopathy, GIST
Interventions
Endoscopic ultrasound fine needle aspiration
Device
Lead sponsor
Mauna Kea Technologies
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Atlanta, Georgia • Manhasset, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Oct 18, 2026, 8:16 AM EDT
Completed Phase 2 Interventional

Treatment of Hepatitis C in Hemophilic Patients With HIV

NCT00055341
View directory record Official record
Conditions
HIV Infections, Hepatitis C, Hemophilia
Interventions
Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Oct 18, 2026, 8:16 AM EDT
Completed No phase listed Observational Results available

IL-17 Neutrophils in CF Lung Inflammation

NCT02025829
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 18, 2026, 8:16 AM EDT
Active, not recruiting No phase listed Observational

Pulmonary Vascular Disease in CF

NCT04549077
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 21 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Indianapolis, Indiana • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 18, 2026, 8:16 AM EDT
Completed No phase listed Observational

Screening for Gynecologic Cancers in Hereditary Nonpolyposis Colorectal Cancer (HNPCC) Patients

NCT00508846
View directory record Official record
Conditions
Colon Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
25 Years and older · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 18, 2026, 8:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Nuclear Morphology of Breast Cells in Ductal Lavage

NCT00259597
View directory record Official record
Conditions
Benign Breast Disease
Interventions
breast ductal lavage
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Oct 18, 2026, 8:16 AM EDT
Recruiting Phase 2 Interventional

Phase 2 Study to Assess the Safety and Efficacy of ANG003

NCT07450547
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Interventions
ANG003 Dose A, ANG003 Dose B, Creon
Drug
Lead sponsor
Anagram Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
27
States / cities
Long Beach, California • Los Angeles, California • Denver, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 18, 2026, 8:16 AM EDT
Recruiting Phase 1 Interventional

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

NCT04715191
View directory record Official record
Conditions
Liver Cancer, Rhabdomyosarcoma, Malignant Rhabdoid Tumor, Liposarcoma, Wilms Tumor, Yolk Sac Tumor
Interventions
CARE T cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2042
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 18, 2026, 8:16 AM EDT
Completed Phase 2 Interventional Results available

Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer

NCT02961374
View directory record Official record
Conditions
Attenuated Familial Adenomatous Polyposis, Familial Adenomatous Polyposis
Interventions
Erlotinib, Erlotinib Hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 69 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
7
States / cities
Scottsdale, Arizona • Ann Arbor, Michigan • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 18, 2026, 8:16 AM EDT
Completed No phase listed Observational

Genomic Research in Alpha-1 Antitrypsin Deficiency

NCT01832220
View directory record Official record
Conditions
Alpha 1 Antitrypsin Deficiency, AATD
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
40 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
9
States / cities
Tucson, Arizona • San Francisco, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Oct 18, 2026, 8:16 AM EDT